Animal Type Segment Analysis: Companion Animals (Largest & Fastest-Growing Segment)

In the veterinary immunodiagnostics market, the companion animals segment accounted for the largest share of 80.85% in 2026 and also emerged as the fastest-growing segment. This leadership is primarily supported by the increasing rate of pet ownership, rising expenditure on animal healthcare, and growing awareness among pet owners regarding the importance of early disease detection. Companion animals often receive routine preventive care and diagnostic screening, which has strengthened the adoption of immunodiagnostic testing across veterinary practices. The segment’s continued growth is further driven by advances in veterinary medicine, expanding availability of specialized diagnostic services, and the increasing humanization of pets. Owners are increasingly seeking accurate and timely diagnosis for infectious diseases, allergies, and chronic health conditions, encouraging wider use of immunodiagnostic solutions. As veterinary care standards continue to evolve, demand for reliable testing among companion animal populations is expected to remain particularly strong.

End-user Segment Analysis: Veterinary Reference Laboratories (Largest Segment) vs Point-of-care/in-house Testing (Fastest-Growing Segment)

Holding the largest share of the veterinary immunodiagnostics market, the veterinary reference laboratories segment accounted for 60.95% in 2026. These laboratories benefit from access to advanced testing infrastructure, skilled personnel, and the ability to process large volumes of samples with high levels of accuracy. Veterinary clinics frequently rely on reference laboratories for comprehensive diagnostic evaluations, particularly for complex disease investigations and specialized immunological testing.

The point-of-care/in-house testing segment is witnessing the fastest growth due to the growing preference for rapid diagnostic results within veterinary facilities. Increasing demand for immediate clinical decision-making, reduced turnaround times, and improved treatment outcomes is encouraging veterinary hospitals and clinics to adopt in-house testing capabilities. Technological improvements in compact diagnostic platforms are further supporting the expansion of this segment by making advanced testing more accessible at the point of care.

Product Segment Analysis: Lateral Flow Assays (Largest Segment) vs Lateral Flow Rapid Tests (Fastest-Growing Segment)

The veterinary immunodiagnostics market was led by the lateral flow assays segment, which held a dominant share of 83.3% in 2026. The segment’s strong position is attributed to its simplicity, affordability, and ability to deliver reliable diagnostic results without requiring sophisticated laboratory infrastructure. These assays are widely utilized for detecting infectious diseases and monitoring animal health across both clinical and field settings, making them a preferred diagnostic format for veterinary professionals.

Lateral flow rapid tests represent the fastest-growing product segment, supported by increasing demand for convenient and immediate diagnostic solutions. Veterinary practitioners are increasingly adopting rapid testing methods to accelerate diagnosis and initiate treatment without delays. The expanding need for portable, user-friendly testing tools in both companion animal and livestock healthcare settings is further contributing to the rising adoption of lateral flow rapid tests.